Skip to main content
SpringerLink
Log in

Experimental reproduction of catecholamine-depleted states and parkinsonism — Theoretical and practical aspects

  • Reviews
  • Published:
Neurophysiology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literature cited

  1. N. N. Anosov, "The shaking palsy or paralysis agitans (Parkinson's disease)," in: Guide to Neurology, Vol. 7 [in Russian], S. N. Davidenkov, ed., Medgiz, Moscow (1960), pp. 256–280.

    Google Scholar 

  2. M. Ya. Voloshin, L. F. Burchinskaya, V. S. Zelenskaya, and G. N. Shevko, "Compensation for motor impairment and regeneration processes in the nigrostriatal system and thalamus following systemic administration of the neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)," in: Plasticity of the Nervous System, Vol. 18 [in Russian], O. S. Andrianov, ed., Moscow (1989), pp. 142–144.

  3. M. Ya. Voloshin, E. P. Lukhanina, B. P. Kolomiets, et al., "Effects of lesioning the nigrostriatal dopaminergic system induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on excitatory and inhibitory processes in neurons of thalamic motor nuclei," Neirofiziologiya,21, No. 5, 620–629 (1989).

    Google Scholar 

  4. E. I. Kandel, Functional and Stereotaxic Neurosurgery [Russian translation], Meditsina, Moscow (1981).

    Google Scholar 

  5. G. N. Kryzhanovskii, M. A. Atadzhanov, V. A. Zagorevskii, et al., "Experimentally-induced Parkinson's syndrome produced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine," Byull. Éksp. Biol. Med.,105, No. 4, 397–401 (1988).

    Google Scholar 

  6. R. P. Kucherenko, "Morphological rearrangement of cell elements in the ventral tegmental region produced by selective lesioning of catecholaminergic brain systems," Arkh. Anat. Embriol.,93, No. 12, 11–17 (1987).

    Google Scholar 

  7. E. P. Lukhanina, "Effects of systemic administration of neuroleptics on neuronal background activity in the cat ventrolateral thalamic nucleus," Neirofiziologiya,21, No. 5, 675–685 (1989).

    Google Scholar 

  8. N. N. Oleshko, "Role of the dopaminergic system in the development of caudate-induced spindling activity in the cat," Fiziol. Zh.,32, No. 3, 263–272 (1986).

    Google Scholar 

  9. V. A. Otellin, R. P. Kucherenko, E. G. Gilerovich, et al., "Morphological rearrangement induced in the brain by a decline in catecholamine level," Zh. Nevropatol. Psikhiatr.,84, No. 7, 978–981 (1984).

    Google Scholar 

  10. K. B. Shapovalova, "Conditioned reflex postural readjustment in dogs following systemic administration of dopaminergic substances," Zh. Vyssh. Nerv. Deyat.,34, No. 6, 1057–1065 (1984).

    Google Scholar 

  11. K. B. Shapovalova and A. F. Yakimovskii, "Involvement of nigrostriatal and mesolimbic dopaminergic brain systems in controlling components of acquired motor response in dogs," Fiziol. Zh. SSSR,73, No. 5, 579–589 (1987).

    Google Scholar 

  12. Y. Agid, F. Javoy, J. Glowinski, et al., "Injection of 6-hydroxydopamine into substantia nigra of the rat. II. Diffusion and specificity," Brain Res.,58, No. 2, 291–301 (1973).

    Google Scholar 

  13. N. E. Andén, A. Dahlström, K. Fuxe, et al., "Ascending monoamine neurons to the telencephalon and diencephalon," Acta Physiol. Scand.,67, No. 3/4, 313–326 (1966).

    Google Scholar 

  14. K. S. Bankiewicz, E. H. Oldfield, C. C. Chiueh, et al., "Hemiparkinsonism in monkey after unilateral internal carotid artery infusion of MPTP," Life Sci.,39, No. 1, 7–16 (1986).

    Google Scholar 

  15. A. Barbeau, L. Dallaire, N. T. Bun, et al., "New amphibian models for study 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)," Life Sci.,36, No. 11, 1125–1134 (1985).

    Google Scholar 

  16. A. Björklund and O. Lindvall, "Dopamine-containing systems in the CNS," in: Handbook of Chemical Neuroanatomy, Vol. 2, Pt. 1, A. Björklund and T. Hökfelt, eds., Elsevier, Amsterdam (1984), pp. 55–122.

    Google Scholar 

  17. W. Birkmayer, J. Knoll, P. Riederer, et al., "Increased life expectancy resulting from addition of 1-deprenyl to Madopar treatment in Parkinson's disease: a long-term study," J. Neural Trans.,64, No. 1, 113–127 (1985).

    Google Scholar 

  18. W. J. Brooks, M. F. Jarvis, and G. C. Wagner, "Astrocytes as a primary focus of the conversion of MPTP into MPP+," J. Neural Trans.,76, No. 1, 1–12 (1989).

    Google Scholar 

  19. A. Carlsson, "Dopaminergic autoreceptors," in: Chemical Tools in Catecholamine Research, Vol. 2, O. Alngren et al., eds., Elsevier, Amsterdam (1975), pp. 219–224.

    Google Scholar 

  20. A. Carlsson, "Antipsychotic agents: elucidation of their mode of action," in: Discoveries in Pharmacology, Ch. 4, Pt. 3, M. J. Parnham and J. Bruinvels, eds., Elsevier, Amsterdam (1983), pp. 197–206.

    Google Scholar 

  21. A. Carlsson and D. Waldeck, "A fluorimetric method for determination of dopamine (3-hydrotyramine)," Acta Physiol. Scand.,44, No. 3/4, 293–298 (1958).

    Google Scholar 

  22. D. Clark and F. J. White, "Review: D1 dopamine receptor — the search for a function. A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications," Synapse,1, No. 2, 347–388 (1987).

    Google Scholar 

  23. R. J. Coleman, F. Grandas-Perez, N. Quinn, et al., "(+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models," in: Parkinson's Disease: Clinical and Experimental Advances, F. C. Rose, ed., John Libbey, London-Paris (1987), pp. 179–188.

    Google Scholar 

  24. J. T. Coyle, "Neuron-specific cytotoxins," in: Handbook of Neurochemistry, Vol. 9, A. Lajtha, ed., Plenum Press, New York-London (1985), pp. 299–329.

    Google Scholar 

  25. A. R. Crossman, "Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders," Neuroscience,21, No. 1, 1–40 (1987).

    Google Scholar 

  26. A. R. Crossman and M. A. Sambrook, "Experimental torticollis in the monkey produced by unilateral 6-hydroxydopamine brain lesions," Brain Res.,149, No. 2, 498–502 (1978).

    Google Scholar 

  27. R. J. D'Amato, Z. P. Lipman, and S. H. Snyder, "Selectivity of parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin," Science,231, No. 4741, 987–989 (1986).

    Google Scholar 

  28. R. J. D'Amato, G. M. Alexander, and R. G. Schwartzman, "Neuromelanin: a role in MPTP-induced neurotoxicity," Life Sci.,40, No. 8, 705–712 (1987).

    Google Scholar 

  29. A. Dahlström and K. Fuxe, "Evidence of the existence of monoamine-containing neurons in the central neurvous system. 1. Demonstration of monoamines in the cell bodies of brain stem neurons," Acta Physiol. Scand., Suppl.232, 1–55 (1964).

    Google Scholar 

  30. G. C. Davis, A. C. Williams, S. P. Markey, et al., "Chronic parkinsonism secondary to intravenous injection of meperidine analogues," Psychiatr. Res.,1, No. 2, 249–254 (1979).

    Google Scholar 

  31. A. D. Degryse and F. Colpaert, "Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in old Java monkey (Macaca cynomolgus fascicularis) (Raffles)," Brain Res. Bull.,16, No. 5, 561–571 (1989).

    Google Scholar 

  32. R. C. Duvoisin, "Etiology of Parkinson's disease: current concepts," Clin. Neuropharmacol.,9, Suppl. 1, S3-S11 (1989).

    Google Scholar 

  33. M. Filion, L. Tremblay, and P. J. Bédard, "Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkey," Brain Res.,444, No. 1, 165–176 (1988).

    Google Scholar 

  34. T. L. Frigyesi, A. Ige, A. Iulo, and R. Schwartz, "Denigration and sensorimotor disability induced by ventral tegmental injection of 6-hydroxydopamine in the cat," Exp. Neurol.,33, No. 1, 78–87 (1971).

    Google Scholar 

  35. W. R. G. Gibb, "The Lewy body and Parkinson's disease," in: Parkinson's Disease: Clinical and Experimental Advances, F. C. Rose, ed., John Libbey, London-Paris (1987), pp. 3–12.

    Google Scholar 

  36. M. Goldstein, B. Anagnoste, W. S. Owen, and A. F. Battista, "The effects of ventromedial tegmental lesions on the disposition of dopamine in the caudate nucleus of the monkey," Brain Res.,4, No. 1, 298–300 (1967).

    Google Scholar 

  37. M. Goldstein, A. F. Battista, T. Ohmoto, et al., "Tremor and involuntary movements in monkeys: effect of 1-dopa and of dopamine receptors stimulating agents," Science,179, No. 4075, 816–817 (1973).

    Google Scholar 

  38. R. E. Heikkila, A. Hess, and R. C. Duvoisin, "Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice," Science,224, No. 4656, 1451–1453 (1984).

    Google Scholar 

  39. R. E. Heikkila, A. Hess, and R. C. Duvoisin, "Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: relationship between monoamine oxidase, MPTP metabolism, and neurotoxicity," Life Sci.,36, No. 3, 231–236 (1985).

    Google Scholar 

  40. O. Hornykiewicz, "Brain dopamine in Parkinson's disease and other neurological disturbances," in: The Neurobiology of Dopamine, A. S. Horn, et al., eds., Academic Press, London (1979), pp. 633–654.

    Google Scholar 

  41. T. Hökfelt and U. Ungerstedt, "Specificity of 6-hydroxydopamine induced degeneration on central monoamine neurons: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigrostriatal dopamine system," Brain Res.,60, No. 2, 269–279 (1973).

    Google Scholar 

  42. R. Iansek, "The effects of reserpine on motor activity and pallidal discharge in monkeys: implications for the genesis of akinesia," J. Physiol.,301, 457–466 (1980).

    Google Scholar 

  43. J. A. Javitch, R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder, "Parkinsonism-induced neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity," Proc. Natl. Acad. Sci.,82, No. 7, 2173–2177 (1985).

    Google Scholar 

  44. P. Jenner and C. D. Marsden, "MPTP-induced parkinsonism in primates and its use in the assessment of novel strategies for the treatment of Parkinson's disease," in: Parkinson's Disease: Clinical and Experimental Advances, F. C. Rose, ed., John Libbey, London-Paris (1987), pp. 149–162.

    Google Scholar 

  45. J. N. Johannessen, C. C. Chiueh, R. S. Burns, and S. P. Markey, "Differences in the metabolism of MPTP in rodent and primate parallel differences in sensitivity to its neurotoxic effects," Life Sci.,36, No. 3, 219–224 (1985).

    Google Scholar 

  46. G. Jonsson, "Chemical lesioning techniques: monoamine neurotoxins," in: Handbook of Chemical Neuroanatomy, A. Björklund and T. Hökfelt, eds., Elsevier, Amsterdam (1983), pp. 463–507.

    Google Scholar 

  47. J. W. Kebabian and D. B. Calne, "Multiple receptors for dopamine," Nature,277, No. 5692, 93–96 (1979).

    Google Scholar 

  48. H. Kinemuchi, C. J. Fowler, and K. F. Tipton, "The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease," Neurochem. Int.,11, No. 4, 359–373 (1987).

    Google Scholar 

  49. S. Kuzuhara, H. Mori, N. Izumiyama, et al., "Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study," Acta Neuropathol.,75, No. 4, 345–353 (1988).

    Google Scholar 

  50. J. W. Langston, "From behavioral model to molecular mechanisms: MPTP as a tool to study Parkinson's disease," in: Parkinson's Disease: Clinical and Experimental Advances, F. C. Rose, ed., John Libbey, London-Paris (1987), pp. 137–148.

    Google Scholar 

  51. J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, "Chronic parkinsonism in humans due to product of meperidine-analog synthesis," Science,219, No. 4587, 979–980 (1983).

    Google Scholar 

  52. J. W. Langston, L. S. Forno, C. S. Rebert, and I. Irwin, "Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in squirrel monkey," Brain Res.,292, No. 2, 390–394 (1984).

    Google Scholar 

  53. J. W. Langstone, I. Irwin, and G. A. Ricaurte, "Neurotoxins, parkinsonism, and Parkinson's disease," Pharmacol. Therap.,32, No. 1, 19–49 (1987).

    Google Scholar 

  54. L. Larochelle, P. Bedard, R. Boucher, and L. J. Poirier, "The rubro-olivo-cerebello-rubral loop and postural tremor in the monkey," J. Neurol. Sci.,11, No. 1, 53–64 (1970).

    Google Scholar 

  55. P. Levitt, J. E. Pintar, and X. O. Breakfield, "Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotoninergic neurons," Proc. Natl. Acad. Sci.,79, No. 20, 6385–6389 (1982).

    Google Scholar 

  56. I. Libman, M. J. Gawel, R. J. Riopelle, and S. Bouchard, "A comparison of bromocriptine (parlodel) and levodopacarbidopa (Sinemet) for treatment of ‘de novo’ Parkinson's disease patients," Can. J. Neurol. Sci.,14, No. 4, 576–580 (1987).

    Google Scholar 

  57. O. Lindvall, S. B. Dunnett, P. Brundin, and A. Björklund, "Transplantation of catecholamine-producing cells to the basal ganglia in Parkinson's disease: experimental and clinical studies," in: Parkinson's Disease: Clinical and Experimental Advances, F. C. Rose, ed., John Libbey, London-Paris (1987), pp. 189–206.

    Google Scholar 

  58. R. K. Mishara, A. M. Marshall, and S. L. Varmuza, "Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes," Brain Res.,200, No. 1, 47–57 (1980).

    Google Scholar 

  59. J. W. Nicklas, I. Vyas, and R. E. Heikkila, "Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine," Life Sci.,36, No. 26, 2503–2508 (1985).

    Google Scholar 

  60. S. P. Onn, T. W. Berger, E. M. Stricker, and M. J. Zigmond, "Effects of the intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis," Brain Res.,376, No. 1, 8–19 (1986).

    Google Scholar 

  61. J. E. Parisi and R. S. Burns, "The neuropathology of MPTP-induced parkinsonism in man and experimental animals," in: MPTP: a Neurotoxin Producing a Parkinsonian Syndrome, S. P. Markey et al., eds., Academic Press, Orlando (1986), pp. 141–148.

    Google Scholar 

  62. T. L. Perry, V. W. Yong, R. M. Clavier, et al., "Partial protection from neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse," Neurosci. Lett.,60, No. 2, 109–114 (1985).

    Google Scholar 

  63. L. J. Poirier, "Experimental and histological study of mid-brain dyskinesias," J. Neurophysiol.,23, No. 5, 534–545 (1960).

    Google Scholar 

  64. P. Riederer and M. B. H. Youdim, "MPTP induced dopaminergic neurotoxicity — a useful model in the study of Parkinson's disease," Neurochem. Int.,11, No. 4, 379–381 (1987).

    Google Scholar 

  65. C. Sachs and G. Jonsson, "Selective 6-hydroxy-DOPA induced degeneration of central and peripheral noradrenaline neurons," Brain Res.,40, No. 3, 563–568 (1972).

    Google Scholar 

  66. J. S. Schneider, A. Yuwiler, and C. H. Markham, "Production of a parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry," Exp. Neurol.,91, No. 2, 293–307 (1986).

    Google Scholar 

  67. W. Schultz, "MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity, and pathophysiology," Gen. Pharmacol.,19, No. 2, 153–161 (1988).

    Google Scholar 

  68. P. Seeman and H. B. Niznik, "Dopamine D1 receptor pharmacology," ISI Atlas Sci.: Pharmacology,2, No. 2, 161–170 (1988).

    Google Scholar 

  69. L. S. Seiden and G. Vosmer, "Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methamphetamine," Pharmacol. Biochem. Behav.,21, No. 1, 29–31 (1984).

    Google Scholar 

  70. M. Smialek, T. E. Bugera-Piecuch, and B. Kosicka, "Effect of ascorbic acid on dopamine level in the mouse brain after intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)," Neuropathol. Pol.,25, No. 3, 299–304 (1987).

    Google Scholar 

  71. P. Sokoloff, M. P. Martres, and J. C. Schwartz, "Three classes of dopamine receptor (D2, D3, D4) identified by binding studies with 3H-apomorphine and 3H-domperidone," Naunyn-Schmiedebergs Arch. Pharmacol.,315, No. 1, 89–102 (1980).

    Google Scholar 

  72. U. Understedt and G. W. Arbuthnott, "Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system," Brain Res.,24, No. 3, 485–493 (1970).

    Google Scholar 

  73. G. C. Wagner and M. F. Jarvis, "Age-dependent effects of MPTP," in: MPTP: a Neurotoxin Producing a Parkinsonian Syndrome, S. P. Markey et al., eds., Academic Press, Orlando (1986), pp. 461–464.

    Google Scholar 

  74. J. S. Wilson and J. A. Wilson, "Intracellular recordings in the caudate nucleus in normal and MPTP-treated dogs," in: MPTP: a Neurotoxin Producing a Parkinsonian Syndrome, S. P. Markey et al., eds., Academic Press, Orlando (1986), pp. 695–699.

    Google Scholar 

Download references

Authors
  1. M. Ya. Voloshin
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

A. A. Bogomolets Institute of Physiology, Academy of Sciences of the Ukrainian SSR, Kiev. Translated from Neirofiziologiya, Vol. 22, No. 3, pp. 401–414, May–June, 1990.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voloshin, M.Y. Experimental reproduction of catecholamine-depleted states and parkinsonism — Theoretical and practical aspects. Neurophysiology 22, 296–306 (1990). https://doi.org/10.1007/BF01052641

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01052641

Keywords

Search

Navigation